Study of Ravulizumab in Pediatric Participants With Primary IgAN
Status:
RECRUITING
Trial end date:
2028-11-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with ravulizumab IV in pediatric participants to support the extrapolation of efficacy from the adult population.